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CEREBROSPINAL FLUID BIOMARKERS

Deciphering the factors that influence participation in studies
requiring serial lumbar punctures
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Abstract
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Missouri, USA

Introduction: Cerebrospinal fluid biomarkers increasingly inform the causes of dementia and may provide objective markers of disease progression. There is a need to deci-

2 Washington University School of Medicine, St.

pher participant and procedural factors that promote participation in studies incorpo-
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rating longitudinal biomarker measures.
Methods: Participant and procedural factors associated with participation in longitudinal biomarker studies were determined in individuals enrolled in studies of memory and
aging at the Knight Alzheimer Disease Research Center (Saint Louis, MO, USA).
Results: Complications were encountered following 331 of 1484 lumbar punctures
(22.3%; LPs), affecting 280 of 929 participants (30.1%); in >95% complications were
minor. Three hundred fifteen of 679 eligible participants (46.4%) completed multiple
LPs. Younger age (odds ratio [OR] 2.08 per decade [95% confidence interval (CI) 1.61–
2.94]), normal cognition (OR 21.4 [2.85–160.1]), and the absence of heart disease (OR
2.0 [1.01–3.85]) or seizures at study entry identified participants with increased odds
of completing three or more LPs.
Discussion: Factors influencing participation may be leveraged to improve recruitment
and retention within observational and therapeutic studies requiring serial LPs.
KEYWORDS
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1

BACKGROUND

the central nervous system; and can be safely and efficiently sampled
from individuals with all levels of cognitive impairment,9,10 informing

Biomarkers are used increasingly to determine the cause of

the dynamic relationship between biomarkers and symptomatic

dementia,1–4 define the biochemical changes that influence rates

expression of disease.11,12

and identify individuals at high risk of

Despite the high value placed on CSF in research,13 participants

developing dementia who may benefit from therapeutic interventions

express low enthusiasm for participation in studies requiring lumbar

of disease

progression,5,6

Cerebrospinal

puncture (LP).14 Several factors contribute to this reticence, including

fluid (CSF) biomarkers are ideal for this purpose, as CSF is sensitive

concerns regarding the safety of the procedure.14,15 Although LP is

to the early changes associated with the most common cause of

typically safe, complications are encountered in research and clinical

dementia, Alzheimer’s disease (AD)8 ; can be analyzed simultaneously

settings. Most commonly, these complications include mild self-limited

for multiple analytes that directly reflect biochemical changes within

low-back pain or headache, with medical intervention limited to

designed to delay or prevent cognitive

impairment.7
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the <5% of participants who require an autologous blood patch for
the treatment of post-dural puncture headache.15–20 Prior research

RESEARCH IN CONTEXT

in this area has shown that fearfulness of LP is reduced in participants

1. Systematic review: The authors reviewed the literature

who have previously completed a successful LP,14 suggesting that

using traditional sources (eg, PubMed). Despite increas-

these participants should be more willing to participate in subsequent

ing interest in the use of longitudinal biomarker measures

LPs. However, retention within studies requiring serial LPs remains

in dementia research,11–13 no studies considered how to

challenging.

promote engagement within studies incorporating serial

There is a need to promote participant enrollment and engage-

cerebrospinal fluid (CSF) measures.

ment within research studies requiring serial LPs, yet the factors that

2. Interpretation: Age, cognitive status, and health history

influence longitudinal participation are largely unknown. Recognizing

at study entry independently influenced odds of partic-

this, we evaluated the participant and procedural factors that asso-

ipation in serial lumbar punctures (LPs) in community-

ciated with serial LP completion by community-dwelling participants

dwelling older adults enrolled in prospective studies of

enrolled within longitudinal studies of memory and aging at the Knight

memory and aging. This information can be leveraged to

Alzheimer Disease Research Center (ADRC; Washington University

promote recruitment of individuals who are more likely

School of Medicine; Saint Louis, MO, USA). Emphasis was placed on

to agree to longitudinal CSF sampling, and to enhance

identifying potentially modifiable factors that could be targeted to pro-

retention of enrolled participants who are likely to decline

mote retention in longitudinal research studies, including prior history
of LP complications.

requests for subsequent LPs.
3. Future directions: Strategies are needed to reduce
burden associated with participation in longitudinal
biomarker research. Particular attention should be paid

2

METHODS

to the needs of older, cognitively impaired participants
with medical comorbidities.

2.1 Standard protocol approvals, registrations,
and patient consents
This nested-cohort study included data from prospectively evaluated
community-dwelling individuals enrolled within longitudinal studies of

from longitudinal analyses. Participants prescribed dual antiplatelet

memory and aging at the Knight ADRC between January 2004 and

therapies were counseled to hold one anti-platelet agent 7 days before

April 2018. Eligible participants completed at least one clinical assess-

their planned LP. If their prescribing physician deemed this unsafe,

ment and research LP, and consented to the use of information and

an LP was not scheduled and they were excluded from longitudinal

CSF specimens for research purposes. Study procedures and policies

analyses. Similarly, LPs were not performed in participants with other

were approved by the Washington University School of Medicine Insti-

known contraindication (eg, space-occupying cerebral lesion, ongoing

tutional Review Board.

anticoagulant therapy25 ), and they were excluded from longitudinal
analyses.
On the day of the LP, participants were informed of the rationale

2.2 Clinical assessments and research lumbar
punctures

for the LP and associated risks. Participants were counseled to avoid
strenuous activity for 24 hours following the procedure and to hydrate
with clear fluids and caffeinated beverages if desired. All participants

Beginning in 2004, newly enrolled research participants agreed in

were instructed to notify study personnel if concerning symptoms

principle to undergo an LP for research purposes at study entry and

or side effects developed following the LP, and were reassured that

every 3 years thereafter. Exceptions were made for African Amer-

access to a blood patch would be provided by study-affiliated physi-

ican participants, with the intent to improve representation within

cians if required to treat post-dural puncture headache. LPs were

research, irrespective of opportunities to measure CSF biomarkers.

completed by experienced neurologists using established protocols

Prior to undergoing an LP, participants were evaluated by expe-

in consented individuals.26 Briefly, LPs were performed in the early

rienced clinicians using semi-structured interviews with both the

morning (between 0730 and 0900 hours) on fasted participants.

participant and a knowledgeable collateral source, and a detailed

Unless contraindicated, participants were seated in a massage chair,

neurologic examination of the participant.21 When appropriate,

and local analgesia accomplished with 1% lidocaine injected subcu-

diagnoses of dementia were rendered by study clinicians, integrating

taneously via a 25-gauge needle. CSF was sampled using a 22-gauge

results from the clinical assessment and bedside measures of cognitive

atraumatic (“non-cutting”) Sprotte needle, advanced between the

function, referencing established diagnostic criteria.22,23 The severity

L3/L4 or L4/L5 vertebrae. If CSF could not be accessed using standard

of cognitive impairment was staged using the global Clinical Dementia

techniques, the operating clinician could reattempt the procedure with

Rating (CDR) scale.24 Participants with moderate or severe dementia

the participant in the lateral decubitus position. Conventional (“cut-

(CDR ≥2) were not asked to undergo serial LPs and were excluded

ting”) spinal needles (22-gauge) were available upon request by the
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operating clinician. Deviances from standard procedures and intraprocedural LP complications were documented prospectively by the study
coordinator.
Following the LP, participants were provided with breakfast and
observed for 1 hour before discharge home. Participants were encouraged to lie supine throughout the observation period, although this

TA B L E 1
puncture

Participant characteristics

Participants (n = 929)

Age, mean (±SD), years

68.7 (9.3)

Sex, female, n (%)

492 (53.0)

Race, n (%)

was not strictly enforced. All participants were reached by telephone
within 24 hours and queried concerning post-procedural side effects.
Additional follow-up calls established the natural history of post-LP

for treatment provided when appropriate. Complications that resolved

Non-Hispanic white

834 (89.8)

African American

86 (9.3)

Other

complications when necessary. All complaints and concerns were
reviewed with study physicians and patients were recommendations

Participant characteristics at the time of first lumbar

Education, mean (±SD), years

9 (1.0)
15.9 (2.7)

Cognitive status, n (%)

within 24 hours with rest and over-the-counter analgesics were graded

Cognitively normal

690 (74.3)

as mild (eg, back pain at the site of needle insertion). Moderate compli-

Symptomatic Alzheimer’s disease

163 (17.5)

cations included those that persisted beyond 24 hours. Complications

Other dementia

76 (8.2)

requiring medical evaluation or physician-directed intervention

APOE𝜀4 carrier, n (%)

(namely a blood patch) were graded as severe. Autologous blood

355/876 (40.5)

APOE, apolipoprotein; SD, standard deviation.

patch was offered to any patient who fulfilled International Classification of Headache Disorders Criteria III for post-dural puncture
headache,27 and in whom headache persisted for >24 hours despite

2.4

Data availability

implementation of conservative management strategies (rest, hydration, and analgesia). Autologous blood patches were undertaken by

Study data are available to qualified investigators upon approval of

experienced anesthesiologists, targeting the general proximity of the

a resource request by the Knight ADRC Data Request Committee

prior LP.

(https://knightadrc.wustl.edu/research/resourcerequest.htm).

2.3

3

Data analysis

Demographic, clinical, and LP data were available from all participants

3.1

RESULTS
Participant demographics

who completed one or more research LPs. Additional data concerning
apolipoprotein epsilon (APOE𝜀) genotype and AD biomarkers (CSF

Between January 2004 and May 2018, a total of 929 participants com-

levels of amyloid 𝛽 [A𝛽]40–42 , total-tau, and phosphorylated-tau;

pleted 1484 LPs. Participant characteristics at the time of their first

measured using the Elecsys assay as previously reported28 ) were

LP are detailed in Table 1. Participants were well educated, with ages

available from a majority of participants. Participants who were eligi-

spanning mid-to-late life (range, 42.7- to 99.4-years old). The majority

ble to complete two or more consecutive LPs were defined as “serial

of participants were non-Hispanic white and cognitively normal (CDR

completers.”

0), and reflected the characteristics of the surrounding community.

Demographic and clinical details were summarized using descrip-

AD was the most common cause of cognitive impairment (163/239,

tive statistics and the frequency of LP complications determined

68.2%), with most affected participants exhibiting very mild (CDR 0.5;

across participants. Demographic and participant and procedural

n = 111, 68.1%) or mild dementia (CDR 1; n = 48, 29.4%) at study entry.

factors associated with post-LP complications and serial completion

Participants with moderate severity AD dementia (CDR 2; n = 4, 2.5%)

of LP studies were evaluated using the chi-square or Fisher exact tests

at study entry were not asked to complete subsequent LPs.

for categorical variables and Student t (independent variables) for
continuous variables. Variables implicated as potential contributors to
post-LP complications or serial completion of LP studies on univariate

3.2

Lumbar puncture complications

analyzes (P < 0.05) were further evaluated using multivariable logistic
regression (forced entry), allowing the effect of variables on the

Complications were reported following 331 LPs (22.3%), affecting 280

outcome of interest to be quantified while adjusting for confounding

(30.1%) distinct participants (Table 2). More than 95% of complications

variables. Variables were excluded if data were missing from >10%

resolved within 24 hours without medical intervention and were

of eligible individuals. Model explanatory power was assessed using

deemed minor. Severe complications requiring medical intervention

the c-statistic (area under the receiver operating characteristic [ROC]

were limited to the 38 participants (2.6%) with unremitting post-dural

curve). Statistical analyses were conducted using SPSS Statistics

puncture headaches who required autologous blood patches. Univari-

(IBM Corp., Version 24.0. Armonk, NY). Statistical significance was

ate comparisons suggested that complications were overrepresented

established at P < 0.05.

in younger, female, and cognitively normal participants with a history

4 of 9
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Complications reported following 1484 lumbar

lower body mass index, and fewer years of operator experience
were associated with severe complications (Table 3). When these

Lumbar puncture complications

n (%)

variables were considered together via multivariable logistic regres-

Headachea

166 (11.2)

sion, younger age, female sex, cognitive normal status, and use of

Mild

115 (7.7)

a traumatic needle independently predicted an increased odds of a

Moderate

13 (0.9)

post-LP complication (n = 1360). Younger age, lower body mass index

Severe

38 (2.6)

Back pain

[BMI], and fewer years of clinician experience performing LPs were
independent predictors of severe complications (n = 1386; Appendix

141 (9.5)

Vasovagal response

56 (3.8)

Syncope

26 (1.8)

A). In general, the multivariable model demonstrated a modest ability
to identify participants who were likely to experience any complication
(c-statistic, any complication = 0.65 [95% CI 0.61-0.68], P < 0.001),

Mild headache = self-resolving without medical intervention within
24 hours; moderate headache = lasting >24 hours; severe = requiring blood
patch or hospitalization.
a

suggesting that unmeasured participant or procedural risk factors
also influenced LP complications. By contrast, the model accurately
identified participants likely to experience a severe complication
(c-statistic, severe complication = 0.84 [95% CI 0.79-0.90], P < 0.001).

of dyslipidemia, cardiovascular disease, or prior LP complication, and
normal A𝛽 42 levels. Complications were also associated with the use

3.3

of a non-Sprotte (cutting needle) and the volume of CSF withdrawn.

Participation in serial lumbar punctures

The mean difference in CSF volume between participants with and
without a complication was <1 cc, and was deemed unlikely to be

Rates of participation in serial LPs among eligible participants declined

clinically relevant. Younger age, female sex, cognitively normal status,

following the first and second LPs before plateauing (Figure 1).

TA B L E 3

Association between participant and procedural factors and post-LP complications
Any complication, n = 331

Measured variables

Present

Severe complication, n = 38
P value

Present

69.2 (8.9)

<0.001

60.5 (9.7)

<0.001

Absent

Absent

P value

Participant-specific factors at time of first LP
Age, mean (±SD), years

65.8 (8.9)

Female sex, n (%)

218 (65.9)

610 (52.9)

Education, mean (±SD), years

16.0 (2.4)

16.0 (2.7)

0.94

Non-Hispanic white, n (%)

298 (90.0)

1037 (89.9)

0.96

Cognitively normal, n (%)

294 (88.9)

919 (79.7)

<0.001

Low CSF A𝛽 42 , n (%)

130 (39.4)

526 (46.1)

0.03

BMI, mean (±SD), kg/m2

27.5 (5.9)

27.9 (5.4)

0.23

APOEɛ4 carrier, n (%)

68.7 (8.9)

<0.001

800 (55.3)

0.02

16.0 (2.6)

0.60

37 (97.3)

1298 (89.8)

0.17a

36 (94.7)

1177 (81.4)

0.04

28 (73.7)
16.2 (2.4)

16 (42.1)
23.5 (3.3)

640 (44.6)
27.9 (5.5)

0.76
<0.001

112 (35.9)

427 (39.3)

0.27

15 (41.7)

524 (38.5)

0.70

Cardiovascular disease, n (%)

60 (18.1)

283 (24.5)

0.02

5 (13.2)

338 (23.4)

0.14

Cerebrovascular disease, n (%)b

11 (4.4)

42 (4.8)

0.81

2 (7.1)

51 (4.6)

0.38a

125 (40.1)

541 (51.1)

0.001

9 (32.0)

657 (48.9)

0.08

32 (9.7)

98 (8.5)

0.51

0

130 (9.0)

0.07a

Hypertension, n (%)

137 (43.8)

485 (45.2)

0.66

9 (30.0)

613 (45.2)

0.10

Mood disorder, n (%)

70 (21.1)

223 (19.3)

0.47

4 (10.5)

289 (20.0)

0.15

6 (2.0)

27 (2.6)

0.55

1 (2.6)

32 (2.4)

0.61a

Smoking history, n (%)b

125 (47.9)

428 (44.9)

0.39

13 (38.2)

540 (45.8)

0.39

Thyroid disease, n (%)

51 (15.4)

203 (17.6)

0.35

6 (15.8)

248 (17.2)

0.83

4.5 (4.1)

4.4 (4.1)

0.56

2.6 (2.2)

331 (15.4)

124 (10.8)

0.02

1 (2.6)

Dyslipidemia, n (%)
Diabetes, n (%)

Seizures, n (%)

Procedure-specific factors
Operator experience, mean (±SD), years
Any prior LP complication, n (%)
Traumatic needle, n (%)
Lateral decubitus position, n (%)
Volume of CSF collected, mean (±SD), mLb
a

Fisher exact test.

b Data missing for >10% of events.

a

4.4 (4.1)

0.006

174 (12.0)

0.12

0

20 (1.4)

>0.99a

52 (3.6)

0.64a

9 (2.7)

11 (1.0)

0.03

15 (4.5)

37 (3.2)

0.25

0

24.3 (2.6)

25.0 (2.3)

0.001

25.4 (2.5)

24.8 (2.4)

0.35
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F I G U R E 1 Rates of participation in serial lumbar punctures (LPs) at study entry and every 3 years thereafter. Participants eligible to complete
serial LPs (black) are shown alongside of those who successfully completed serial LPs (gray). Rates of completion (solid line) demonstrate that
participation rates declined from the first (study entry) to the third LP (year 6), before plateauing

The participant and procedural factors associated with serial LP

Younger age, lower BMI, and fewer years of clinician experience

completion are detailed in Table 4. Younger age, female sex, greater

performing LPs were all associated with greater odds of a severe com-

years of education, cognitively normal status, normal CSF A𝛽 42 levels,

plication (namely, post-dural puncture headache). Other complications

and the absence of cardiovascular disease, dyslipidemia, hypertension,

occurred following an additional 19.7% of LPs. Most of the compli-

or prior history of LP complication were overrepresented in partici-

cations were mild and self-resolving and did not influence odds of

pants completing two or more LPs. Similar factors were associated with

participation in a subsequent LP. Only younger age, normal cognition,

completion of three or more LPs, with the exception of a history of dys-

and the absence of heart disease or history of seizure disorder at study

lipidemia and prior LP complication (no longer associated) and seizures

entry increased the odds of participation in serial (≥3) LPs.

(now associated). Multivariable logistic regression established younger

Rates and types of post-LP complications in community-dwelling

age, and cognitively normal status as independent predictors of serial

volunteers in our studies were consistent with those reported in

completers (≥2 LPs; data from 678 eligible participants were included

cohorts including patients for whom mild self-limiting side effects

in the model). Unexpectedly, abnormally low CSF A𝛽 42 levels were also

occurred following 11% to 30% of LPs, and more serious complica-

associated with greater odds of completing two or more LPs, when

tions requiring intervention (eg, blood patch for post-dural puncture

accounting for the effects of other variables, including cognitive status

headache) were encountered in <5%.15–20 Similar factors predis-

(Figure 2, Panel A). Young, cognitively normal participants without a

posing to post-LP complications were identified in the largest of

prior history of heart disease exhibited the greatest odds of completing

these cohorts—a multi-center study performing LPs in 3456 unique

three or more LPs (data from 406 eligible participants were included in

patients at 23 European memory clinics.17 Age <65 years, absence

the model). No participants with a reported seizure disorder completed

of a dementia diagnosis, and use of a traumatic (cutting) needle were

≥3 LPs (Figure 2; Appendix B). Model statistics confirmed fair ability

also associated with increased risk of post-dural puncture headache

of the model to predict serial completion (c-statistic, ≥2 LPs = 0.79

in this multicenter study. Uniquely, this study also identified a prior

[95% CI 0.76-0.83], P < 0.001; c-statistic, ≥3 LPs = 0.78 [95% CI

history of headache, patient-expressed fears of post-LP complications,

0.73-0.82], P < 0.001). Of interest, after controlling for the effect of

use of larger bore needle (<22 gauge), and upright positioning as

other variables, a prior history of LP complication (including severe

key participant and procedural risk factors for moderate-to-severe

complication) did not deter participants from participating in serial

post-dural puncture headaches.17 Female sex was not associated with

LPs.

any increased risk of complications,17 contrasting findings in this and
other cohorts.29,30 Taken together, this information can be leveraged
to improve informed consent, providing individual participants with

4

DISCUSSION

a realistic expectation of procedural risks. By identifying participants
at the greatest risk of moderate-to-severe complications, it may also

Complications requiring medical intervention occurred following 2.6%

be possible to implement risk-reduction strategies, including the use

of 1484 LPs performed in 929 older community-dwelling participants

of smaller gauge needles and lateral decubitus positioning in select

enrolled in longitudinal studies of memory and aging at our center.

individuals.15,17,18
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Association between participant and procedural factors and completion of serial LPs
Eligible to complete ≥2 consecutive LPs (n = 679)

Measured variables

Completed

Eligible to complete ≥3 consecutive LPs (n = 432)

Not completed

P value

Completed

Not completed

P value

<0.001

61.7 (8.6)

69.0 (9.3)

<0.001

Participant-specific factors at time of first LP
Age, mean (±SD), years

65.3 (8.0)

72.0 (7.9)

Female sex, n (%)

184 (58.4)

178 (48.9)

Education, mean (±SD), years

16.2 (2.5)

15.6 (2.9)

0.01

16.1 (2.4)

15.7 (2.8)

0.15

Non-Hispanic white, n (%)

280 (88.9)

329 (90.4)

0.52

114 (90.5)

258 (90.8)

0.91

Cognitively normal, n (%)

300 (95.2)

224 (61.5)

<0.001

125 (99.2)

222 (78.2)

<0.001

97 (30.9)

176 (48.4)

<0.001

31 (24.8)

112 (39.4)

0.004

Low CSF A𝛽, n (%)

0.01

78 (61.9)

143 (50.3)

0.03

BMI, mean (±SD), kg/m2

27.9 (5.7)

27.3 (4.9)

0.14

APOEɛ4 carrier, n (%)

106 (35.9)

144 (42.9)

0.08

41 (34.5)

99 (38.4)

0.46

53 (16.8)

114 (0.31)

<0.001

14 (11.1)

70 (24.7)

0.002

6 (2.3)

18 (5.6)

0.05

3 (3.2)

10 (4.1)

>0.99a

103 (39.8)

165 (51.6)

0.005

40 (42.1)

117 (49.4)

0.23

Cardiovascular disease, n (%)
Cerebrovascular disease, n (%)b
Dyslipidemia, n (%)b
Diabetes, n (%)

28.0 (4.8)

27.7 (5.3)

0.60

25 (7.9)

31 (8.5)

0.78

9 (7.1)

21 (7.4)

0.93

Hypertension, n (%)b

103 (39.3)

157 (47.9)

0.04

33 (34.4)

113 (46.1)

0.049

Mood disorder, n (%)

57 (18.1)

80 (22.0)

0.21

17 (13.5)

54 (19.0)

0.17

5 (1.6)

14 (3.9)

0.07

10 (3.6)

0.03

136 (43.9)

173 (48.7)

0.24

59 (46.8)

128 (46.7)

0.98

46 (14.6)

49 (13.5)

0.69

19 (15.0)

38 (13.4)

0.65

Any LP complication, n (%)

73 (23.2)

62 (17.0)

0.046

25 (19.8)

60 (21.1)

0.77

Severe LP complication, n (%)

11 (3.5)

11 (3.0)

0.73

6 (4.8)

13 (4.6)

0.94

Seizures, n (%)
Smoking history, n (%)

b

Thyroid disease, n (%)

0

Procedure-specific factors

a
b

Fisher exact test.
Data missing for >10% of events.

Clinician experience performing LPs was inversely correlated with

No participants in our study required hospitalization for management

the odds of severe LP complications in our study. This finding adds to

of post-LP complications (vs 23 [0.7%] patients17 ). It is unclear whether

a growing body of literature reporting positive correlations between

early use of autologous blood patches may mitigate symptom duration

clinician experience and patient confidence and operator stress and

and the need for additional medical intervention or hospitalization.

procedural complications,31 and suggests that clinician experience (or

Uniquely, this study identified independent predictors of partici-

lack thereof) may contribute to the wide variability in complication

pation in serial LPs, including younger age, absence of cardiovascular

rates reported across studies.15–20 Accordingly, clinician experience

disease or seizure disorder, and normal cognition at study entry.

may represent an important modifiable procedural risk factor, raising

Although the majority of these factors are associated with longevity,

the possibility that additional training aimed at reducing clinician

their selection was not attributable to a survival effect, noting that

stress and promoting familiarity with the procedure may reduce

only participants who were eligible to complete a diagnostic LP were

procedural complications while increasing participant confidence and

included in the longitudinal analyses (ie, participants who died, with-

comfort.

drew from the study, or developed an uncorrectable contraindication

Standard procedures in our study included the use of a 22-gauge

for LP25 were excluded). Thus, it is more likely that advancing age,

atraumatic needle in seated (upright) volunteers. These differences

declining cognition, and the presence of comorbidities associated

may have contributed to the higher incidence of complications requir-

with frequent medication use (including antiplatelet agents) identified

ing medical intervention in our cohort (2.6% [38/1484]) versus those

participants who were most likely to perceive LPs as burdensome.

reported in another large study (1.0% [33/3456]17 ). However, this dif-

This information can be used to promote recruitment of individuals

ference also may reflect the low threshold for offering and performing

who are most likely to agree to longitudinal CSF sampling, while

blood patch in volunteers in our study, owing to the ease of accessibil-

focusing retention efforts on participants who are at-risk of declining

ity of blood patches at our center, history of excellent response in par-

future LPs. Such efforts could include targeted educational campaigns

ticipants, and desire to minimize duration of symptoms in community-

emphasizing the importance of longitudinal biomarker measures in

dwelling volunteers. Indeed, blood patches were performed in 38 of 41

aging research (eg, see 32–34), in combination with practical initiatives

(93%) of participants with post-LP headache lasting >24 hours in our

aimed at reducing burden for aging cognitively impaired participants

study, but only 11 of 470 (2.3%) of patients in the Duit et al. cohort.17

with increasing medical comorbidities.
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F I G U R E 2 Factors influencing participation in serial lumbar punctures (LPs). Odds ratios ± 95% confidence intervals are shown for factors
associated with participation in ≥2 (Panel A) and ≥3 consecutive LPs. No participant with a prior history of seizure disorder completed ≥3 LPs (OR
≈ 0; not shown)

This nested cohort study leveraged data from a large cohort of participants enrolled in studies of memory and aging at a single center.

CSF sampling, including both observational and clinical/therapeutic
studies.

Although prospective collection of information is a strength, the parent studies were not designed to measure participant and procedural
factors associated with participation in biomarker substudies. Accord-

5

CONCLUSIONS

ingly, data were not available concerning several factors that may
have influenced complications and longitudinal participation. Partici-

Younger, cognitively normal participants without known heart disease

pant perceptions concerning LPs are one such factor, with participant

or seizure disorder at study entry were more likely to participate in

anxiety and fear known to associate with complications and reticence

studies requiring serial CSF sampling. Prior history of LP complications

to participate in LPs.15,17,18,20 In addition, it is unknown whether rapid

did not influence participation in LP studies when controlling for the

access to blood patches—a unique feature of this study—influenced

effect of other variables. Knowledge of the participant and procedural

participation in serial LPs. Reassurance of access to blood patches

specific factors that influence participation in studies requiring serial

for the treatment of post-dural puncture headaches may represent

CSF sampling may be leveraged to promote recruitment and retention

one means of assuaging participant concerns regarding diagnostic LPs,

within studies requiring serial LPs.

although we acknowledge that the expertise and resources required to
support this initiative may not be readily transferable to other research
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